166 related articles for article (PubMed ID: 37224415)
21. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
22. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
23. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
24. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
Tröltzsch M; Tröltzsch M; Pautke C; Otto S
HNO; 2022 Jul; 70(7):499-507. PubMed ID: 35050392
[TBL] [Abstract][Full Text] [Related]
25. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
26. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
27. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
[TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Medication-Related Osteonecrosis of the Jaws without Segmental Resections: A Case Series.
Fernandes TL; Viezzer Fernandes B; Franco GCN
Am J Case Rep; 2024 Feb; 25():e942980. PubMed ID: 38404023
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
32. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.
Sturrock A; Preshaw PM; Hayes C; Wilkes S
BMJ Open; 2019 Mar; 9(3):e024376. PubMed ID: 30833319
[TBL] [Abstract][Full Text] [Related]
33. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw.
Chopra K; Malhan N
Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592
[TBL] [Abstract][Full Text] [Related]
34. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
[TBL] [Abstract][Full Text] [Related]
35. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.
Soares AL; Simon S; Gebrim LH; Nazário ACP; Lazaretti-Castro M
Support Care Cancer; 2020 May; 28(5):2265-2271. PubMed ID: 31468192
[TBL] [Abstract][Full Text] [Related]
37. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
38. Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients.
Borumandi F; Aghaloo T; Cascarini L; Gaggl A; Fasanmade K
Anticancer Agents Med Chem; 2015; 15(6):736-43. PubMed ID: 25807940
[TBL] [Abstract][Full Text] [Related]
39. Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing.
Zheng Y; Dong X; Chen S; He Y; An J; Liu M; He L; Zhang Y
BMC Oral Health; 2023 Jan; 23(1):14. PubMed ID: 36627695
[TBL] [Abstract][Full Text] [Related]
40. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday.
Hamid A; Thomas S; Bell C; Gormley M
Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
